<DOC>
	<DOCNO>NCT02951182</DOCNO>
	<brief_summary>This Phase 2 , randomize , double-blind , placebo- active-controlled , parallel group , multicenter study evaluate safety , tolerability , efficacy VX-440 dual triple combination tezacaftor ( TEZ ; VX-661 ) ivacaftor ( IVA ; VX-770 ) subject cystic fibrosis ( CF ) homozygous F508del mutation CF transmembrane conductance regulator ( CFTR ) gene ( F508del/F508del ) , heterozygous F508del mutation minimal function ( MF ) CFTR mutation likely respond TEZ and/or IVA therapy ( F508del/MF ) .</brief_summary>
	<brief_title>A Study Evaluating Safety Efficacy VX-440 Combination Therapy Subjects With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Willing able comply schedule visit , treatment plan , study restriction , laboratory test , contraceptive guideline , study procedure . To prevent pregnancy , female participant childbearing potential male partner require use prespecified , highly effective method nonhormonal contraception . Male participant female partner childbearing potential require use condom . Body weight ≥35 kg . Sweat chloride value ≥60 mmol/L test result obtain screen . Subjects must eligible CFTR genotype : Heterozygous F508del minimal function ( MF ) mutation know predict responsive TEZ and/or IVA . Homozygous F508del Subjects must FEV1 ≥40 % ≤90 % predict normal age , sex , height Screening Visit Stable CF disease judge investigator . Willing remain stable CF medication regimen plan end treatment , applicable , Safety Follow Visit . History comorbidity , opinion investigator , might confound result study pose additional risk administer study drug subject . History cirrhosis portal hypertension . Risk factor Torsade de Pointes History hemolysis . Glucose6phosphate dehydrogenase ( G6PD ) deficiency assess Screening . Clinically significant abnormal laboratory value screen An acute upper low respiratory infection , pulmonary exacerbation , change therapy pulmonary disease within 28 day first dose study drug . Lung infection organisms associate rapid decline pulmonary status An acute illness relate CF within 14 day first dose study drug A standard digital ECG demonstrate QTc &gt; 450 msec screening . History solid organ hematological transplantation . History evidence cataract lens opacity determine clinically significant ophthalmologist optometrist base ophthalmologic examination Screening Period . History alcohol drug abuse past year , include limited , cannabis , cocaine , opiates , deem investigator . Ongoing prior participation investigational drug study , certain exception . ( e.g. , ongoing participation NCT02565914 ) Use commercially available CFTR modulator ( e.g. , Kalydeco , Orkambi ) within 14 day screen ( applies Heterozygous F508del/MF cohort ; apply Homozygous F508del/F508del Cohort ) . Pregnant nursing female : Females childbearing potential must negative pregnancy test screen Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>